Key points
- Global Travelan sales up 70% in Q4 2024 vs prior quarter, up 249% on pcp
- Australia Travelan sales up 83% in Q4 2024 vs prior quarter, up 314% on pcp
- North America Travelan sales up 43% in Q4 2024 vs prior quarter, up 141% on pcp
Full summary
Immuron Limited, an Australian-based and globally integrated biopharmaceutical company, has announced continued strong sales growth (unaudited) of its over-the-counter immune supplement Travelan. In the December 2024 quarter, global Travelan sales increased by 70% to AUD$2.5 million compared to the prior quarter, and were up 249% year-on-year. In Australia, Travelan sales increased by 83% in the December 2024 quarter compared to the prior quarter, and were up 314% year-on-year. In North America, Travelan sales increased by 43% in the December 2024 quarter compared to the prior quarter, and were up 141% year-on-year. For the December 2024 half-year, global Travelan sales were AUD$4.0 million, up 70% on the prior corresponding period. In Australia, Travelan sales for the half-year were AUD$2.9 million, up 54% on the prior corresponding period. In North America, Travelan sales for the half-year were AUD$1.1 million, up 130% on the prior corresponding period.